Drug Discovery and Development 1st October – 31st January 2027 has launched.
Dedicated to the needs of biotech and pharma leaders, this heavyweight journal of pharma intelligence serves to advance drug discovery into active medical solutions, from development and formulation to post approval – into the complexities of manufacturing and commercialisation.
This edition explores key therapeutic fields on:
- diabetes and endocrinology
- infectious diseases and vaccines
- as well as immunology and autoimmune diseases.
This edition also explores:
• Novel biomarkers and their impact
• Biologics including advances in antibody-drug conjugates and the translational gap
• AI in drug discovery and development
• Drug manufacturing: from drug approval to commercialisation
• Manufacturing different modalities and processes – complex biologics, peptides, continuous manufacturing, fill and finish and how to tailor this to your needs
• Contamination Control Strategy
• Regulatory updates, environmental analysis and much more.
Part of Pharma Press Global, based in London, UK, Drug Discovery and Development’s targeted audience is spilt between North America and Europe, with a strong focus on biologics.
Drug Discovery and Development is a subscription-only journal, published three times a year.
Please email subs@pharmapress.co.uk to purchase a print subscription.
